Published March 28, 2024
| Version v2
Journal article
Open
Antibody Characterization Report for ACSL5 (Long-chain-fatty-acid--CoA ligase 5)
Creators
-
1.
Montreal Neurological Institute and Hospital
-
2.
Structural Genomics Consortium
-
3.
University of Toronto
- 4. Advanced BioImaging Facility (ABIF)
- 5. McGill University
- 6. The Neuro's Early Drug Discovery Unit (EDDU)
Description
This report presents a guide to selecting high-quality commercial antibodies against Long-chain-fatty-acid--CoA ligase 5 (ACSL5) by western blot, immunoprecipitation and immunofluorescence, using a standardized experimental protocol comparing read-outs in knockout cell lines and isogenic parental controls.
This study was funded in part by the ALS-Reproducible Antibody Platform (ALS-RAP), established as a public-private partnership by three prominent ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
Files
ACSL5_YCharOS report - v2.pdf
Files
(2.7 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:c59eddd10282b6b05013d742f13b1320
|
2.7 MB | Preview Download |
Additional details
Dates
- Submitted
-
2024-03-18